1-(1,3-苯并二氧戊环-5-基)-1-异丙基脲 | 33095-94-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: 1-(1,3-苯并二氧戊环-5-基)-1-异丙基脲
• 英文名称: N-isopropyl-N-[3,4-(methylenedioxy)phenyl]urea
• 英文别名: N-isopropyl-N-<3,4-(methylenedioxy)phenyl>urea；1-(1,3-benzodioxol-5-yl)-1-isopropylurea；N-isopropyl-N-(3,4-methylenedioxyphenyl)urea；1-(1,3-benzodioxol-5-yl)-1-propan-2-ylurea
• CAS: 33095-94-2
• 化学式: C₁₁H₁₄N₂O₃
• 分子量: 222.244
• InChiKey: CHOBLILHXVGGLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  64.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  1-(1,3-苯并二氧戊环-5-基)-1-异丙基脲 在 potassium permanganate 、 甲烷磺酸 作用下， 以 1,4-二氧六环 、 水 、 甲苯 为溶剂， 反应 21.0h， 生成 1-isopropyl-4-(p-methylphenyl)-6,7-methylenedioxy-2(1H)-quinazolinone
  参考文献：
  名称：

  8-芳基-5-异丙基-2H-1,3-二氧杂环戊并[4,5-g]喹唑啉-6（5H）-ones和-thiones的抗炎特性。

  摘要：

  DOI：

  10.1021/jm00351a022
• 作为产物：
  描述：

  3,4-亚甲二氧基苯胺 在 三乙胺 作用下， 以 甲醇 、 溶剂黄146 为溶剂， 反应 67.0h， 生成 1-(1,3-苯并二氧戊环-5-基)-1-异丙基脲
  参考文献：
  名称：

  1-烷基-4-芳基-3,4-二氢-2（1 H）-喹唑啉酮和硫酮。合成和1 H-NMR光谱

  摘要：

  通过修饰Pictet-Spengler反应制备一系列的1-烷基-4-芳基-3,4-二氢-2（1 H）-喹唑啉酮和硫酮，其中涉及处理N-烷基-N-芳基脲或在甲磺酸存在下，将硫脲与芳基醛进行反应。这些化合物中的几种的1 H-nmr光谱引起异常的OCH 2 O和异丙基信号。

  DOI：

  10.1002/jhet.5570190639

文献信息

• Substituted quinazolines and analogs and use thereof
  申请人：Euro-Celtique S.A.

  公开号：US06465472B1

  公开（公告）日：2002-10-15

  The invention relates to novel quinazolines and heterocycles which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, myoclonus. Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition and learning enhancers.

  该发明涉及新型喹唑啉和杂环化合物，它们是AMPA受体的拮抗剂或正调节剂，用于治疗、预防或改善与中风、全脑和局部缺血、中枢神经系统创伤、低血糖和手术相关的神经元丧失，以及治疗或改善包括阿尔茨海默病、肌萎缩侧索硬化、亨廷顿病、帕金森病和唐氏综合征在内的神经退行性疾病，治疗、预防或改善兴奋性氨基酸过度刺激的不良后果，治疗、预防或改善焦虑、精神病、抽搐、慢性疼痛、青光眼、视网膜炎、尿失禁、肌肉痉挛和诱导麻醉，以及治疗或改善兴奋性氨基酸缺乏的不良后果，如精神分裂症、肌阵挛、阿尔茨海默病和营养不良和神经发育不良，以及作为认知和学习增强剂。
• N-(3,4-methylenedioxy-phenyl)ureas
  申请人：Sandoz, Inc.

  公开号：US03997564A1

  公开（公告）日：1976-12-14

  Disclosed are compounds of the class of 1-alkyl-4-phenyl and 4-(2-thienyl)-6,7-methylenedioxy-2(1H)-quinazolinones and quinazolinthiones, including the 3,4-dihydro derivatives thereof, useful as pharmaceutical agents, e.g. as anti-inflammatory agents. Such compounds, e.g. 1-isopropyl-4-phenyl-6,7-methylenedioxy-2(1H)-quinazolinones and 1-isopropyl-4-phenyl-6,7-methylenedioxy-2(1H)-quinazolinthiones, may be prepared by reacting the corresponding N-alkyl-N-(3,4-methylenedioxyphenyl)urea or thiourea with an aromatic aldehyde, e.g. benzaldehyde, in the presence of an acid at elevated temperatures to obtain the 3,4-dihydro-2(1H)-quinazolinones or 3,4-dihydro-2(1H)-quinazolinthiones which may then be oxidized to the corresponding 3,4-unsaturated compounds.

  本发明公开了一种1-烷基-4-苯基和4-(2-噻吩基)-6,7-亚甲二氧基-2(1H)-喹唑啉酮和喹唑啉硫酮类化合物，包括其3,4-二氢衍生物，作为药物，例如作为抗炎药物。这些化合物，例如1-异丙基-4-苯基-6,7-亚甲二氧基-2(1H)-喹唑啉酮和1-异丙基-4-苯基-6,7-亚甲二氧基-2(1H)-喹唑啉硫酮，可以通过将相应的N-烷基-N-(3,4-亚甲二氧基苯基)脲或硫脲与芳香醛（例如苯甲醛）在酸的存在下在高温下反应，得到3,4-二氢-2(1H)-喹唑啉酮或3,4-二氢-2(1H)-喹唑啉硫酮，然后可以将其氧化为相应的3,4-不饱和化合物。
• Substituted quinazolines and analogs and the use thereof
  申请人：Euro-Celtique S.A.

  公开号：US20030033089A1

  公开（公告）日：2003-02-13

  The invention relates to novel quinazolines and heterocycles which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, myoclonus, Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition and learning enhancers.

  本发明涉及新型的喹唑啉和杂环化合物，它们是AMPA受体的拮抗剂或正向调节剂，并用于治疗、预防或改善与中风、全局和局部缺血、中枢神经系统创伤、低血糖和手术相关的神经元丧失，以及治疗或改善包括阿尔茨海默病、肌萎缩性侧索硬化、亨廷顿病、帕金森病和唐氏综合症在内的神经退行性疾病，治疗、预防或改善兴奋性氨基酸过度刺激的不良后果，治疗、预防或改善焦虑、精神病、惊厥、慢性疼痛、青光眼、视网膜炎、尿失禁、肌肉痉挛和诱导麻醉，以及治疗或改善兴奋性氨基酸缺乏的不良后果，如精神分裂症、肌阵挛、阿尔茨海默病和营养不良和神经发育不良，并作为认知和学习增强剂。
• Substituted 1(2H)-phthalazinones and pharmaceutical compositions thereof
  申请人：Euro-Celtique S.A.

  公开号：US07652006B2

  公开（公告）日：2010-01-26

  The invention relates to novel quinazolines and heterocycles which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, myoclonus, Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition and learning enhancers.

  本发明涉及新型喹唑啉和杂环化合物，其为AMPA受体的拮抗剂或正调节剂，并用于治疗、预防或改善与中风、全局和局部缺血、中枢神经系统创伤、低血糖和手术相关的神经元丧失，以及治疗或改善包括阿尔茨海默病、肌萎缩性侧索硬化症、亨廷顿病、帕金森病和唐氏综合症在内的神经退行性疾病，治疗、预防或改善兴奋性氨基酸过度刺激的不良后果，治疗、预防或改善焦虑、精神病、惊厥、慢性疼痛、青光眼、视网膜炎、尿失禁、肌肉痉挛和诱导麻醉，以及治疗或改善兴奋性氨基酸缺乏引起的不良后果，如精神分裂症、肌阵挛、阿尔茨海默病和营养不良和神经发育不良，并作为认知和学习增强剂。
• HOULIHAN, W. J.;COOKE, G.;DENZER, M.;NICOLETTI, J., J. HETEROCYCL. CHEM., 1982, 19, N 6, 1453-1456
  作者：HOULIHAN, W. J.、COOKE, G.、DENZER, M.、NICOLETTI, J.

  DOI：——

  日期：——

表征谱图